Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Research Report 2024(Status and Outlook)

Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Research Report 2024(Status and Outlook)



Report Overview:

The Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size was estimated at USD 3623.58 million in 2023 and is projected to reach USD 7544.11 million by 2029, exhibiting a CAGR of 13.00% during the forecast period.

This report provides a deep insight into the global Paroxysmal Nocturnal Hemoglobinuria Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Paroxysmal Nocturnal Hemoglobinuria Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Paroxysmal Nocturnal Hemoglobinuria Drug market in any manner.

Global Paroxysmal Nocturnal Hemoglobinuria Drug Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Apellis Pharmaceuticals

Alexion Pharmaceuticals Inc

Akari Therapeutics Plc

CinnaGen Co

Ra Pharmaceuticals Inc

Amgen Inc

Achillion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Novartis AG

Regeneron Pharmaceuticals Inc

BIOCAD

Samsung Bioepis

Amyndas Pharmaceuticals

Teva Pharmaceutical Industries Ltd.

LGM Pharma.

Lannett

NorthStar Rx LLC

Abbott

Par Pharmaceutical

Market Segmentation (by Type)

Eculizumab

Ravulizumab

Others

Market Segmentation (by Application)

Clinic

Hospital

Others

Geographic Segmentation
  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
  • Industry drivers, restraints, and opportunities covered in the study
  • Neutral perspective on the market performance
  • Recent industry trends and developments
  • Competitive landscape & strategies of key players
  • Potential & niche segments and regions exhibiting promising growth covered
  • Historical, current, and projected market size, in terms of value
  • In-depth analysis of the Paroxysmal Nocturnal Hemoglobinuria Drug Market
  • Overview of the regional outlook of the Paroxysmal Nocturnal Hemoglobinuria Drug Market:
Key Reasons to Buy this Report:
  • Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
  • This enables you to anticipate market changes to remain ahead of your competitors
  • You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
  • The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
  • Provision of market value (USD Billion) data for each segment and sub-segment
  • Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
  • Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
  • Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
  • Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
  • The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
  • Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
  • Provides insight into the market through Value Chain
  • Market dynamics scenario, along with growth opportunities of the market in the years to come
  • 6-month post-sales analyst support
Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Note: this report may need to undergo a final check or review and this could take about 48 hours.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Paroxysmal Nocturnal Hemoglobinuria Drug Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.


1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Paroxysmal Nocturnal Hemoglobinuria Drug
1.2 Key Market Segments
1.2.1 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Type
1.2.2 Paroxysmal Nocturnal Hemoglobinuria Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Paroxysmal Nocturnal Hemoglobinuria Drug Market Overview
2.1 Global Market Overview
2.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Paroxysmal Nocturnal Hemoglobinuria Drug Market Competitive Landscape
3.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Manufacturers (2019-2024)
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Paroxysmal Nocturnal Hemoglobinuria Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Paroxysmal Nocturnal Hemoglobinuria Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Paroxysmal Nocturnal Hemoglobinuria Drug Sales Sites, Area Served, Product Type
3.6 Paroxysmal Nocturnal Hemoglobinuria Drug Market Competitive Situation and Trends
3.6.1 Paroxysmal Nocturnal Hemoglobinuria Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Paroxysmal Nocturnal Hemoglobinuria Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Chain Analysis
4.1 Paroxysmal Nocturnal Hemoglobinuria Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Paroxysmal Nocturnal Hemoglobinuria Drug Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Paroxysmal Nocturnal Hemoglobinuria Drug Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Type (2019-2024)
6.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Market Share by Type (2019-2024)
6.4 Global Paroxysmal Nocturnal Hemoglobinuria Drug Price by Type (2019-2024)
7 Paroxysmal Nocturnal Hemoglobinuria Drug Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Sales by Application (2019-2024)
7.3 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Growth Rate by Application (2019-2024)
8 Paroxysmal Nocturnal Hemoglobinuria Drug Market Segmentation by Region
8.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region
8.1.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region
8.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 Apellis Pharmaceuticals
9.1.1 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.1.2 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.1.3 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.1.4 Apellis Pharmaceuticals Business Overview
9.1.5 Apellis Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug SWOT Analysis
9.1.6 Apellis Pharmaceuticals Recent Developments
9.2 Alexion Pharmaceuticals Inc
9.2.1 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.2.2 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.2.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.2.4 Alexion Pharmaceuticals Inc Business Overview
9.2.5 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug SWOT Analysis
9.2.6 Alexion Pharmaceuticals Inc Recent Developments
9.3 Akari Therapeutics Plc
9.3.1 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.3.2 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.3.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.3.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Drug SWOT Analysis
9.3.5 Akari Therapeutics Plc Business Overview
9.3.6 Akari Therapeutics Plc Recent Developments
9.4 CinnaGen Co
9.4.1 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.4.2 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.4.3 CinnaGen Co Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.4.4 CinnaGen Co Business Overview
9.4.5 CinnaGen Co Recent Developments
9.5 Ra Pharmaceuticals Inc
9.5.1 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.5.2 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.5.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.5.4 Ra Pharmaceuticals Inc Business Overview
9.5.5 Ra Pharmaceuticals Inc Recent Developments
9.6 Amgen Inc
9.6.1 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.6.2 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.6.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.6.4 Amgen Inc Business Overview
9.6.5 Amgen Inc Recent Developments
9.7 Achillion Pharmaceuticals Inc
9.7.1 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.7.2 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.7.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.7.4 Achillion Pharmaceuticals Inc Business Overview
9.7.5 Achillion Pharmaceuticals Inc Recent Developments
9.8 Alnylam Pharmaceuticals Inc
9.8.1 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.8.2 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.8.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.8.4 Alnylam Pharmaceuticals Inc Business Overview
9.8.5 Alnylam Pharmaceuticals Inc Recent Developments
9.9 F. Hoffmann-La Roche Ltd
9.9.1 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.9.2 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.9.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.9.4 F. Hoffmann-La Roche Ltd Business Overview
9.9.5 F. Hoffmann-La Roche Ltd Recent Developments
9.10 Novartis AG
9.10.1 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.10.2 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.10.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.10.4 Novartis AG Business Overview
9.10.5 Novartis AG Recent Developments
9.11 Regeneron Pharmaceuticals Inc
9.11.1 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.11.2 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.11.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.11.4 Regeneron Pharmaceuticals Inc Business Overview
9.11.5 Regeneron Pharmaceuticals Inc Recent Developments
9.12 BIOCAD
9.12.1 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.12.2 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.12.3 BIOCAD Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.12.4 BIOCAD Business Overview
9.12.5 BIOCAD Recent Developments
9.13 Samsung Bioepis
9.13.1 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.13.2 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.13.3 Samsung Bioepis Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.13.4 Samsung Bioepis Business Overview
9.13.5 Samsung Bioepis Recent Developments
9.14 Amyndas Pharmaceuticals
9.14.1 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.14.2 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.14.3 Amyndas Pharmaceuticals Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.14.4 Amyndas Pharmaceuticals Business Overview
9.14.5 Amyndas Pharmaceuticals Recent Developments
9.15 Teva Pharmaceutical Industries Ltd.
9.15.1 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.15.2 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.15.3 Teva Pharmaceutical Industries Ltd. Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.15.4 Teva Pharmaceutical Industries Ltd. Business Overview
9.15.5 Teva Pharmaceutical Industries Ltd. Recent Developments
9.16 LGM Pharma.
9.16.1 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.16.2 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.16.3 LGM Pharma. Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.16.4 LGM Pharma. Business Overview
9.16.5 LGM Pharma. Recent Developments
9.17 Lannett
9.17.1 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.17.2 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.17.3 Lannett Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.17.4 Lannett Business Overview
9.17.5 Lannett Recent Developments
9.18 NorthStar Rx LLC
9.18.1 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.18.2 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.18.3 NorthStar Rx LLC Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.18.4 NorthStar Rx LLC Business Overview
9.18.5 NorthStar Rx LLC Recent Developments
9.19 Abbott
9.19.1 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.19.2 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.19.3 Abbott Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.19.4 Abbott Business Overview
9.19.5 Abbott Recent Developments
9.20 Par Pharmaceutical
9.20.1 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Basic Information
9.20.2 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Overview
9.20.3 Par Pharmaceutical Paroxysmal Nocturnal Hemoglobinuria Drug Product Market Performance
9.20.4 Par Pharmaceutical Business Overview
9.20.5 Par Pharmaceutical Recent Developments
10 Paroxysmal Nocturnal Hemoglobinuria Drug Market Forecast by Region
10.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Forecast
10.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Forecast by Country
10.2.3 Asia Pacific Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Forecast by Region
10.2.4 South America Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Paroxysmal Nocturnal Hemoglobinuria Drug by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Paroxysmal Nocturnal Hemoglobinuria Drug by Type (2025-2030)
11.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Paroxysmal Nocturnal Hemoglobinuria Drug by Type (2025-2030)
11.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Forecast by Application (2025-2030)
11.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Drug Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings